Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Novogen

Novogen's business is in the most pressing area facing medicine in the modern era - that of degenerative diseases and disorders. Cancer Heart disease (stroke, hypertension, coronary artery disease) Osteoporosis Rheumatoid arthritis Inflammatory Bowel Disease (ulcerative colitis, Crohn's Disease) Neurological diseases (Parkinson's Disease, motor neurone disease) Autoimmune diseases (multiple sclerosis, diabetes, lupus etc). While there are drugs available to treat these diseases, they either are poorly effective or only slow the rate of progression of the disease or are associated with unwanted side-effects. Novogen is addressing this urgent area of medical need through the Novogen isoflavonoid technology platform - a platform that the Company believes offers the real prospect of not only treating, but also preventing, the onset of these common degenerative conditions. To meet the challenge of an ambitious target of product development, the Company is structured into four divisions.


Contact Details:
140 Wicks Road
North Ryde
New South Wales
2113
Australia
Tel:+612 9878 0088
Fax:+612 9878 0055
Email:secretary@novogen.com
WWW:

www.novogen.com/




Recent Publications by Novogen:

Sequential microarray to identify timing of molecular responses to Haemonchus contortus infection in sheep.
Anthelmintics are currently the most common method of worm control. The...
3rd June, 2009
Faculty of Veterinary Science, McMaster Building (B14), University of Vet Parasitol. 2009 Apr 6;161(1-2):76-87. Epub 2009 Jan 13.
DOI Direct Link
Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer.
Compounds based on a flavonoid (di-phenolic) ring structure are emerging...
20th September, 2006
Novogen Ltd., North Ryde, NSW, Australia. Mol Biotechnol. 2005 Jul;30(3):253-70.
DOI Direct Link
Flavonoid compounds in the prevention and treatment of prostate cancer.
Compounds based on a flavonoid (di-phenolic) ring structure are emerging...
10th June, 2003
Novogen Limited, North Ryde, Australia. Methods Mol Med. 2003;81:377-94.
DOI Direct Link

Press Releases on Novogen:

BioPortfolio Logo
Glycotex' Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis 7th April, 2009 Glycotex, Inc.
ROCKVILLE, Md., April 7 /PRNewswire/ -- Glycotex, Inc. today announced the completion of a scheduled interim analysis in a Phase II study evaluating the effect of investigational GLYC-101 gel on
Perceptive Informatics Establishes Alliance with AG Mednet to Bring Greater Efficiency and Quality to Medical Imaging-Based Trials 4th February, 2009 PAREXEL International Corporation
Marshall Edwards Accelerates Study Timeline and Experiences Cost Reduction through Perceptive Alliance with AG Mednet BOSTON, Feb. 4 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry
Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing 21st October, 2008 Glycotex, Inc.
ROCKVILLE, Md., Oct. 20 /PRNewswire/ -- Glycotex, Inc. today announced enrollment of the first patient in a Phase IIb study evaluating the effect of GLYC-101 on wound closure and cosmetic outcomes in
Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions 17th October, 2008 Glycotex, Inc.
ROCKVILLE, Md., Oct. 17 /PRNewswire/ -- Glycotex, Inc. today announced that it has finalized an agreement with U.K.-based Advanced Medical Solutions (AMS) to study the use of GLYC-101 with wound
BioSeeker launches new report "The Global Structure of Prostate 1st January, 1970 Bioseeker
  BioSeeker launches new report "The Global Structure of Prostate Cancer R&D" In Europe and the US there are close to 20 million

BioNews Results for Novogen:

Organovo Appoints Robert Baltera to Board
Pharma Live:  Oct 30 2009 6:12PM Matching: novogen
Organovo Appoints Robert Baltera to Board
SmartBrief:  Oct 27 2009 3:57PM Matching: novogen

Novogen Clinical Trials:

Phenoxodiol in Treating Patients With Refractory Solid Tumors

Novogen Patents:

US Patent No.Title
7601855 Substituted chroman derivatives, medicaments and use in therapy
6004558 Methods for treating cancer with legume plant extracts
6146668 Preparation of isoflavones from legumes
6242594 Process for glucan preparation and therapeutic uses of glucan
6340703 Treatment or prevention of osteoporosis

View more Novogen patents.

Novogen (NVGN) Financial information Links from Barchart

NVGN Quote from from Barchart.com
NVGN Chart from from Barchart.com
NVGN Profile from from Barchart.com
NVGN Opinion from from Barchart.com

View more Novogen finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 369 times since April 2007, the link to the organisation's website has been followed 71 times

Recent Search Terms used to find this page: Novogen careers | Novogen careers | novogen careers | novogen careers | novogen email | novogen antibodies | novogen emails | novogen logo | novogen antibodies | .

Search for more companies in North Ryde

Search for more companies in New South Wales



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Novogen

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.